Evidence map›Paper›PMID 39301859›Full record

Trial reportSleep2025

Obstructive sleep apnea and cerebral small vessel disease in community-based older people: an aspirin in reducing events in the elderly imaging substudy.

Stephanie A Ward, Elsdon Storey, Matthew T Naughton, Rory Wolfe, Garun S Hamilton, Meng Law, Ryo Kawasaki, Walter P Abhayaratna, Katherine L Webb, Fergal J O'Donoghue and 12 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01038583 (Aspirin in Reducing Events in the Elderly), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01038583 unknown statusnot on this map

Aspirin in Reducing Events in the Elderly

TypeobservationalSponsorHennepin Healthcare Research InstituteRan2010 to 2024Enrolled19,114ConditionsFunctional Disability, Dementia, Heart Disease, StrokeArms100 mg enteric-coated aspirin, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Development and Validation of Polygenic Scores for Retinal Vessel Calibers.Investigative ophthalmology & visual science · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Stephanie A WardSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Elsdon StoreySchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Matthew T NaughtonThe Department of Respiratory Medicine, Alfred Hospital, and The Central Clinical School, Monash University, Melbourne, VIC, Australia.
Rory WolfeSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-2126-1045
Garun S HamiltonDepartment of Lung, Sleep, Allergy and Immunology, Monash Health, Clayton, VIC, Australia.
Meng LawDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Ryo KawasakiDivision of Public Health, Department of Social Medicine, Graduate School of Medicine, Osaka University, Suita-City, Japan.
Walter P AbhayaratnaCollege of Health and Medicine, Australian National University, Canberra, ACT, Australia.
Katherine L WebbSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-9380-6075
Fergal J O'DonoghueInstitute for Breathing and Sleep, Austin Health, Heidelberg, VIC, Australia.
Danijela GasevicSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Nigel P StocksDiscipline of General Practice, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
Ruth E TrevaksSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Liubov D RobmanSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Scott KolbeDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Sharyn M FitzgeraldSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Suzanne G OrchardSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Tien Y WongSchool of Clinical Medicine, Beijing Tsinghua Changgang Hospital, Tsinghua Medicine, Tsinghua University, Beijing, China.ORCID 0000-0002-8448-1264
John J McNeilSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-1049-5129
Christopher M ReidSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Ben SinclairDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Robyn L WoodsSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.ORCID 0000-0003-1249-6149

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

STUDY

objectivesObstructive sleep apnea (OSA) may increase the risk of dementia. A potential pathway for this risk is through cerebral small vessel disease (CSVD). In the context of an existing randomized trial of aspirin for primary prevention, we aimed to investigate OSA's impact on CSVD imaging measures and explore whether aspirin effects these measures over 3 years that differ in the presence or absence of OSA.

methodsA substudy of the aspirin in reducing events in the elderly (ASPREE) randomized placebo-controlled trial of low-dose aspirin. Community-dwelling participants aged 70 years and above, without cognitive impairment, cardiovascular disease, or known OSA completed an unattended limited-channel sleep study that calculated the oxygen desaturation index and apnea-hypopnea index. At baseline and 3 years later, volumes of white matter hyperintensities (WMH) and silent brain infarctions (SBI) were measured on 1.5 Tesla brain magnetic resonance imaging, and retinal vessel calibers were calculated from retinal vascular imaging.

resultsMild and moderate/severe OSA was detected in 48.9% and 29.9%, respectively, of the 311 participants, who had a mean age of 73.7 years (SD 3.4 years), 38.6% female. OSA of any severity was not associated with WMH volumes, SBI, nor retinal vessel calibers at baseline, nor with change in these measures in the 277 participants with repeated measures acquired after 3 years. OSA of any severity did not interact with aspirin on change in these measures over 3 years.

conclusionsIn healthy older adults undiagnosed OSA was not associated with retinal vascular calibers and neuroimaging measures of CSVD. CLINICAL TRIAL INFORMATION: ASPREE trial has registration with the International Standard Randomized Controlled Trial Number (ISRCTN) www.isrctn.com, ISRCTN83772183 and with www.clinicaltrials.gov, NCT01038583. SNORE-ASA has registration with the Australian New Zealand Clinical Trials Registry (ANZCTR) at www.anzctr.org.au, ACTRN12612000891820.

Indexed as

AspirinCerebral Small Vessel DiseasesSleep Apnea, ObstructiveAgedAged, 80 and overBrainFemaleHumansIndependent LivingMagnetic Resonance ImagingMaleWhite MatterAspirinagingcerebral small vessel diseaseobstructive sleep apneasleep-disordered breathingwhite matter hyperintensities

Identifiers

PMID39301859
PMCPMC11807880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.